Clinical trials: Non Alcoholic Fatty Liver
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage, but will not receive study…
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05560607
- Testing
- AZD7503 Intervention
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
This project, "A double-blind placebo-controlled randomized clinical trial assessing the efficacy of metformin for hepatic fat in adolescents and young adults with polycystic ovary syndrome", proposes exploring the use of novel…
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02500147
- Testing
- Metformin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Fatty Liver, Liver Fibrosis
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- NCT01934777
- Testing
- Docosahexaenoic Acid plus Vitamin E plus choline
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Cirrhosis, Portal Hypertension
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg).
- Conditions
- Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1
- Trial name
- B-REACH (NCT07797101)
- Testing
- Mazdutide injection
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
NASH, NAFLD
Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease
The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of…
- Trial name
- CALIBRE (NCT06879236)
- Where
- Italy
- Volunteers
- 252 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.
- Trial name
- STELLAR-4 (NCT03053063)
- Testing
- SEL
- Where
- 283 sites in United States, Australia and 20 more
- Volunteers
- 883 people
- Sponsor
- Gilead Sciences
NASH - Nonalcoholic Steatohepatitis
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
This is a Phase 2a Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as well as in…
- Trial name
- NCT05415722
- Testing
- TERN-501, TERN-101
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Non-Alcoholic Fatty Liver Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female…
- Trial name
- NCT05203367
- Testing
- BAR502
- Where
- Portugal
- Volunteers
- healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Non-alcoholic Fatty Liver Disease (NAFLD)
Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease
The goal of this open-label, non-randomized, prospective study is to compare Velacur and MRE in all sexes, 18-80 years old with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT05908006
- Testing
- Velacur
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- GI Alliance
NASH - Nonalcoholic Steatohepatitis
Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
The study was planned in 2 parts: Parts A and B. In Part A, we tested 2 single doses of the study medicine in healthy volunteers: 500 mg and 750 mg.
- Trial name
- NCT05441904
- Testing
- PXL770
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Poxel SA
Overweight, Fatty Liver Disease
The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
To assess whether orange peel fermentation has the effect of reducing body fat in adults
- Trial name
- NCT04496895
- Testing
- orange peel fermentation
- Where
- Taiwan
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver.
- Trial name
- NCT04550481
- Testing
- Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease
Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated
- Conditions
- Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma
- Trial name
- NCT07599241
- Testing
- physical activity, usual care
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Non-Alcoholic Fatty Liver Disease
Cigarette Smoking in Non-alcoholic Steatohepatitis
This non-randomized clinical trial was performed to clarify the effect of cigarette smoking reduction on liver function and some anthropocentric indices in smoker patients with non-alcoholic steatohepatitis.
- Trial name
- NCT04688307
- Testing
- Motivational interviewing
- Where
- 2 sites in Iran
- Volunteers
- 104 people
- Sponsor
- Tehran University of Medical Sciences
Nonalcoholic Steatohepatitis
Betaine in Patients With Nonalcoholic Steatohepatitis
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.
- Trial name
- NCT00586911
- Testing
- Cystadane
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Phase 2b Study of GSK4532990 in Adults With NASH
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4).
- Trial name
- HORIZON (NCT05583344)
- Testing
- GSK4532990
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 284 people
- Sponsor
- GlaxoSmithKline
Fatty Liver Disease
Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in our environment. Preliminary data suggest that portal hypertension may exist in the initial phases of NAFLD due to mechanisms that…
- Trial name
- THESIS (NCT04191044)
- Testing
- A complete cardiovascular and liver characterization will be carried out
- Volunteers
- 170 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Aging, Menopause
Gonadal Hormone, Gonadotropin and Cardiovascular Events
Deficiency in gonadal hormone has been considered to play a role in ageing related increased incidence of cardiovascular events. But the mechanism has not been fully elucidated.
- Trial name
- NCT02810821
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shandong Provincial Hospital
Type 2 Diabetes, Pre Diabetes
Multi-morbidity Screening in People With Type 2 Diabetes and Pre Diabetes
People with type 2 diabetes are at risk of complications linked with high blood sugars and these are monitored for in healthcare appointments.
- Conditions
- Type 2 Diabetes, Pre Diabetes, Obstructive Sleep Apnea, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT06053177
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- University of Liverpool
Non Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM.
- Trial name
- NCT01674972
- Testing
- Oral glucose tolerance test
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.